

Vyacheslav G Serpik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5696151/publications.pdf>

Version: 2024-02-01

86
papers

92
citations

1684188
5
h-index

1588992
8
g-index

88
all docs

88
docs citations

88
times ranked

65
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of the Medicinal Products for Human Use Authorised in the Russian Federation. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2022, 12, 79-89.	0.2	3
2	Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation. Farmakoekonomika, 2022, 15, 73-86.	1.2	1
3	Pharmacoeconomic rationale for switching patients with rheumatic diseases from original biologic disease-modifying antirheumatic drugs to biosimilars in context of the Russian healthcare system. Sovremennaya Revmatologiya, 2022, 16, 1-17.	0.5	1
4	Pharmacoeconomic Analysis of R-DA-EPOCH and R-mNHL-BFM-90 Combination Immunochemotherapy in Patients with Prognostically Unfavorable Diffuse Large B-Cell Lymphoma within Randomized Multi-Center Clinical Trial DLBCL-2015. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 321-332.	0.4	3
5	PHARMACOECONOMIC ANALYSIS IN PARENTERAL AND ENTERAL NUTRITION: METHODOLOGICAL FEATURES IN THE CONDITIONS OF RUSSIAN HEALTHCARE. Pharmacoeconomics Theory and Practice, 2021, 9, 6-16.	0.1	0
6	DRUG PROVISION MANAGEMENT TO PROVIDE BETTER ACCESS TO THE HIGH COST TREATMENT AND IMPROVE OUTCOMES – EXAMPLE OF MUCOPOLYSACCHARIDOSIS TYPE II. Pharmacoeconomics Theory and Practice, 2021, 9, 6-11.	0.1	0
7	REVIEW OF THE INTERNATIONAL CLASSIFICATION OF RARE DISEASES. Pharmacoeconomics Theory and Practice, 2021, 9, 18-20.	0.1	1
8	Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 673-680.	1.9	0
9	Pharmacoeconomic evaluation of various treatment options for respiratory distress syndrome in newborns. Voprosy Ginekologii, Akusherstva I Perinatologii, 2021, 20, 155-161.	0.3	1
10	The effectiveness of public spending on the treatment of spinal muscular atrophy in terms of budget impact analysis. Pharmacoeconomics Theory and Practice, 2021, 9, 17-36.	0.1	0
11	PNS36 ECONOMIC EVALUATION OF TOBACCO SMOKING EFFECTS IN THE RUSSIAN FEDERATION. Value in Health, 2020, 23, S290.	0.3	0
12	PDB42 BUDGET IMPACT ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION. Value in Health, 2020, 23, S115-S116.	0.3	0
13	PDB40 COST-EFFECTIVENESS ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION. Value in Health, 2020, 23, S115.	0.3	0
14	PNS12 INTEGRAL SCALE ASSESSMENT FOR PHARMACOECONOMIC EVALUATION FOR REIMBURSEMENT DECISION-MAKING IN THE RUSSIAN FEDERATION. Value in Health, 2020, 23, S286.	0.3	0
15	PRS54 BUDGET IMPACT ANALYSIS OF THE DUPILUMAB IN THE TREATMENT PATIENTS WITH SEVERE BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. Value in Health, 2020, 23, S358.	0.3	0
16	PIH64 ADJUSTED INDIRECT COMPARISON OF THE MEDICINES USING IN CONTROLLED OVARIAN STIMULATION FOR ASSISTED REPRODUCTIVE TECHNOLOGY. Value in Health, 2020, 23, S163-S164.	0.3	0
17	Results of a Sociological Survey on the Needs of Drug Safety Monitoring Specialists for Information on the Creation of the Pharmacovigilance System Master File. Safety and Risk of Pharmacotherapy, 2020, 8, 84-89.	0.2	1
18	PHARMACOECONOMIC EVALUATION OF BIOLOGICAL DRUGS IN THE CROHN'S DISEASE TREATMENT IN THE RUSSIAN FEDERATION. Pharmacoeconomics Theory and Practice, 2020, 8, 6-16.	0.1	0

#	ARTICLE	IF	CITATIONS
19	BUDGET IMPACT ANALYSIS OF SECUKINUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS IN THE RUSSIAN FEDERATION. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 23-28.	0.1	0
20	METHODOLOGICAL ISSUES OF COMPUTATIONS OF THE ENTRY AND DISTRIBUTION OF PATIENTS AND DETERMINING THE COURSE DOSE OF DRUGS IN PHARMACOECONOMIC MODELS. <i>Pharmacoeconomics Theory and Practice</i> , 2020, 8, 6-10.	0.1	0
21	PRS2 COST ANALYSIS FOR THE TREATMENT OF SEVERE UNCONTROLLED BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S77.	1.2	0
22	PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S672-S673.	0.3	0
23	PMD59 COST-EFFECTIVENESS EVALUATION OF PHACOEMULSIFICATION PLATFORMS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S679.	0.3	0
24	PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S575.	0.3	0
25	PDB12 BUDGET IMPACT ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S30.	1.2	0
26	PIH3 BUDGET IMPACT ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S36.	1.2	0
27	PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S903.	0.3	0
28	PSY20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S905.	0.3	0
29	PDB4 COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES. <i>Value in Health Regional Issues</i> , 2019, 19, S29.	1.2	0
30	PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S848.	0.3	0
31	PCV71 INDIRECT COMPARISON OF NEUROPROTECTORS IN THE TREATMENT OF ISCHEMIC STROKE IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S554.	0.3	1
32	PDB10 COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN TYPE 1 DIABETES MELLITUS COMPARED WITH MULTIPLE DAILY INJECTIONS IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S30.	1.2	0
33	PDB29 COST-EFFECTIVENESS ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION. <i>Value in Health</i> , 2019, 22, S577.	0.3	0
34	PDB11 BUDGET IMPACT ANALYSIS OF SWITCHING FROM ALOGLIPTIN TO VILDAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES. <i>Value in Health Regional Issues</i> , 2019, 19, S30.	1.2	0
35	PIH2 COST-EFFECTIVENESS ANALYSIS OF MEDICINES FOR CONTROLLED OVARIAN STIMULATION IN THE TREATMENT OF INFERTILITY IN PATIENTS WITH AN SUBOPTIMAL OVARIAN RESPONSE IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S36.	1.2	0
36	Comparative analysis of the methodology of pharmacoeconomic assessment according to the origin (dated 08.28.2014) and the current (dated 10.29.2018) version of the government degree of the Russian Federation № 871. <i>Pharmacoeconomics Theory and Practice</i> , 2019, 7, 7-16.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Learning Needs as a Reflection of Professional Interests among Health Experts. Safety and Risk of Pharmacotherapy, 2019, 7, 44-52.	0.2	1
38	Pharmacoeconomics of innovations or innovation in pharmacoeconomics: a "relative value" analysis instead of a "cost-effectiveness" analysis?. Pharmacoeconomics Theory and Practice, 2019, 7, 5-8.	0.1	2
39	Health technology assessment of cataract phacoemulsification platforms. Pharmacoeconomics Theory and Practice, 2019, 7, 10-17.	0.1	0
40	Pharmacoeconomic evaluation of baritinib in the treatment of adult patient with moderate to severe rheumatoid arthritis with intolerance or lack of an adequate response to treatment with one or more basic antirheumatic drugs in the Russian Federation. Pharmacoeconomics Theory and Practice, 2019, 7, 19-26.	0.1	0
41	Identification of pharmacoeconomic models attributes. Pharmacoeconomics Theory and Practice, 2019, 7, 5-9.	0.1	0
42	Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. Russian Journal of Cardiology, 2019, , 76-86.	1.4	2
43	PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION. Value in Health, 2018, 21, S412.	0.3	2
44	Pharmacoeconomic evaluation of Secukinumab use as a first- line biologic in patients with psoriatic arthritis. Pharmacoeconomics Theory and Practice, 2018, 6, 20-28.	0.1	2
45	Pharmacoeconomic evaluation of treatment of gastric cancer with ramucirumab in second line. Pharmacoeconomics Theory and Practice, 2018, 6, 26-36.	0.1	0
46	Pharmacoeconomic assessment of the use of dalbavancin (xydalba) in the treatment of skin and soft tissue infections in hospital settings in the Russian Federation. Pharmacoeconomics Theory and Practice, 2018, 5, 67-71.	0.1	0
47	Pharmacoeconomic analysis of vildagliptin in the treatment of type 2 diabetes mellitus. Pharmacoeconomics Theory and Practice, 2018, 6, 5-10.	0.1	0
48	Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making. Value in Health Regional Issues, 2017, 13, 61-66.	1.2	11
49	Economic evaluation of medical care of patients with end-stage dialysis-dependent renal disease. Nephrology and Dialysis, 2017, 19, 389-398.	0.5	0
50	Budget impact analysis of use of BPA anti-inhibitor coagulant complex (aicc) and eptacog alfa [activated] in the prophylaxis of bleedings in inhibitor hemophilia patients. Pharmacoeconomics Theory and Practice, 2017, 5, 13-18.	0.1	0
51	Criteria of efficiency in pharmacoeconomic analysis. Pharmacoeconomics Theory and Practice, 2017, 5, 11-15.	0.1	6
52	Pharmacoeconomic analysis of sofosbuvir for the treatment of chronic hepatitis c (genotype 1) in the russian federation. Pharmacoeconomics Theory and Practice, 2017, 5, 51-61.	0.1	0
53	Selection of a comparison technology for pharmacoeconomic analysis of innovative drugs. Pharmacoeconomics Theory and Practice, 2017, 5, 12-17.	0.1	1
54	Budget Impact Analysis of Medical Care for Chronic Renal Disease Patients in Need of Renal Replacement Therapy Via Peritoneal Dialysis and Hemodialysis in the Russian Health Care Environment. Value in Health, 2016, 19, A130.	0.3	2

#	ARTICLE	IF	CITATIONS
55	Cost-Effectiveness Analysis of Medical Care for Chronic Renal Disease Patients in Need of Renal Replacement Therapy Via Peritoneal Dialysis and Hemodialysis in the Russian Health Care Environment. Value in Health, 2016, 19, A131.	0.3	0
56	Methodology of cost analysis. Pharmacoeconomics Theory and Practice, 2016, 4, 10-14.	0.1	12
57	Methodological issues of pharmacoeconomic modeling. Pharmacoeconomics Theory and Practice, 2016, 4, 13-18.	0.1	4
58	Pharmacoeconomic analysis of hormone medicines used for in vitro fertilization. Pharmacoeconomics Theory and Practice, 2016, 4, 32-38.	0.1	0
59	X National Congress with international participation «Development of pharmacoeconomics and pharmacoepidemiology in the Russian Federation», 4-5 april 2016 Nizhny Novgorod. Pharmacoeconomics Theory and Practice, 2016, 4, 20-22.	0.1	0
60	Pharmacoeconomic analysis of medicines used in the treatment of pulmonary hypertension in the Russian Federation. Pharmacoeconomics Theory and Practice, 2016, 4, 48-53.	0.1	2
61	Cost Of Illness Analysis Of Chronic Kidney Disease In The Entire Population Of The Russian Federation. Value in Health, 2015, 18, A187.	0.3	0
62	Budget Impact Analysis of Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) with Nilotinib as the Second-Line Treatment in Russian Federation. Value in Health, 2015, 18, A442.	0.3	1
63	Methodological basis for budget impact analysis. Pharmacoeconomics Theory and Practice, 2015, 3, 9-12.	0.1	8
64	Budget impact analysis for pharmacological therapy of chronic myeloid leukemia (cml) with nilotinib as the secondline treatment. Pharmacoeconomics Theory and Practice, 2015, 3, 109-114.	0.1	0
65	Pharmacoeconomic study of buserelin-depo in the treatment of hormone-dependent prostate cancer. Pharmacoeconomics Theory and Practice, 2015, 3, 44-47.	0.1	0
66	Pharmacoeconomic evaluation of rare disease management in primary myelofibrosis treatment with ruxolitinib. Pharmacoeconomics Theory and Practice, 2015, 3, 115-118.	0.1	1
67	Pharmacoeconomic analysis of medical care for chronic renal disease patients in need of renal replacement therapy via peritoneal dialysis and hemodialysis in the Russian healthcare environment. Pharmacoeconomics Theory and Practice, 2015, 3, 111-117.	0.1	3
68	Budget Impact Evaluation Of Treatment With A Low Protein Diet And Ketoanalogues Of Essential Aminoacids For Predialysis Patients In Russian Federation. Value in Health, 2014, 17, A467.	0.3	0

